Eli Lilly and Company (NYSE:LLY) Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 228,058 shares of the company's stock after selling 27,437 shares during the quarter. Eli Lilly and Company accounts for about 2.0% of Sarasin & Partners LLP's portfolio, making the stock its 22nd largest holding. Sarasin & Partners LLP's holdings in Eli Lilly and Company were worth $188,355,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. FPC Investment Advisory Inc. boosted its position in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter worth $43,000. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter valued at $48,000. Compass Financial Services Inc purchased a new position in Eli Lilly and Company in the fourth quarter valued at $50,000. Finally, Capital A Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $63,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the subject of several recent analyst reports. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Trading Up 0.9%

Shares of Eli Lilly and Company stock traded up $7.67 during trading hours on Thursday, hitting $816.28. The company's stock had a trading volume of 896,779 shares, compared to its average volume of 3,640,261. The stock has a market cap of $773.62 billion, a price-to-earnings ratio of 69.71, a P/E/G ratio of 1.40 and a beta of 0.41. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm has a fifty day moving average of $771.74 and a 200-day moving average of $800.91.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same period last year, the business earned $2.58 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.